{"url_path":"/sec/otlk/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-060305-index.html","accession_number":"0001104659-26-060305","cik":"0001649989","ticker":"OTLK","issuer_name":"Outlook Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-060305-index.html","primary_entity_key":"0001649989","primary_entity_name":"Outlook Therapeutics, Inc."},"word_count":108,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n**(d) Exhibits.**\n\n \n\nExhibit\n\nNo.\n \nDescription\n\n[5.1](tm2614480d1_ex5-1.htm)\n \n[Opinion of Cooley LLP](tm2614480d1_ex5-1.htm)\n\n[10.1](tm2614480d1_ex10-1.htm)\n \n[At the Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC dated May 13, 2026](tm2614480d1_ex10-1.htm)\n\n[23.1](tm2614480d1_ex5-1.htm)\n \n[Consent of Cooley LLP (included in Exhibit 5.1)](tm2614480d1_ex5-1.htm)\n\n104\n \nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf\nby the undersigned hereunto duly authorized.\n\n \n\n \n**Outlook Therapeutics, Inc.** \n\n \n \n\n \n \n\nDate: May 13, 2026\nBy:\n/s/ Lawrence A. Kenyon * *\n\n \n \nLawrence A. Kenyon\n\n \n \n*Chief Financial Officer*"}